RxDoctor Payments Data

Omar Abbasi, MD

Ophthalmology · Pittsburgh, PANPI 1598967630

Payments from drug & device makers

$36,004in general payments, 2019–2025

Across 260 payments — averaging $138.48 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Bausch & Lomb, A Division Of Bausch Health US, LLC$18K
  • AbbVie$16K
  • Bausch & Lomb Americas Inc.$554
  • Aerie Pharmaceuticals, Inc.$286
  • Regeneron Healthcare Solutions, Inc.$272
  • Novartis$204
  • plus $455 from 10 others

What the payments were for

  • Consulting fees$1,4884%
  • Speaking & faculty fees$27,03875%
  • Travel & lodging$2,4397%
  • Food & beverage$5,00014%
  • Education$400%

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$36,004 in reported general payments places this provider in the 90th percentile of 920 ophthalmology providers in Pennsylvania.

See all ophthalmology providers in Pennsylvania

Medicare billing

Part B allowed, 2024
$195,406
Medicare patients
702
Services billed
2,538

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
LumiganBimatoprost885$419,853
Brimonidine Tartrate-TimololBrimonidine Tartrate/Timolol359$88,339
CombiganBrimonidine Tartrate/Timolol196$76,352
Alphagan PBrimonidine Tartrate135$64,410
VyzultaLatanoprostene Bunod135$63,889
Brimonidine Tartrate897$43,925
RocklatanNetarsudil Mesylat/Latanoprost81$42,377
Latanoprost3,026$40,124
RhopressaNetarsudil Mesylate70$37,639
Cyclosporine54$34,874
Travoprost167$34,663
RestasisCyclosporine27$34,345
Dorzolamide-TimololDorzolamide Hcl/Timolol Maleat1,090$24,363
SimbrinzaBrinzolamide/Brimonidine Tart82$21,226
Prednisolone Acetate368$17,738

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
AbbVieLumigan, Combigan, Alphagan P, Restasis$16,466$594,9611,243 claims
Aerie Pharmaceuticals, Inc.Rocklatan, Rhopressa$286$80,016151 claims
Bausch & Lomb Americas Inc.Vyzulta, Xiidra$554$76,868147 claims
AlconSimbrinza$70$21,22682 claims
Thea Pharma Inc.Iyuzeh$55$3,84313 claims
Bausch & Lomb, A Division Of Bausch Health US, LLCLoteprednol Etabonate$17,767$1,72714 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 90th percentile of 920 ophthalmology providers in Pennsylvania.

Other ophthalmology in Pittsburgh

See the full list for Pennsylvania

Where these figures come from

Is this you, or does something look wrong? →